Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on dermatology. The Company develops improved formulations of known molecules using drug delivery technologies. The Company is engaged in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. The Company has three commercial products and a fourth in development. Its products include Absorica/Epuris, which has isotretinoin as active ingredient; Lipofen, which has fenofibrate as active ingredient, and ConZi/Durela, which has tramadol as active ingredient. The Company is focused on growth through new products and additional out-licensing agreements. The Company also owns seven pre-clinical compounds, including Nanolipolee-007, a liposomal formulation of a plant-derived compound that is a cholesterol-transport inhibitor for the treatment of melanoma and other cancers.